HCW Biologics Inc. (NASDAQ:HCWB) Sees Significant Decrease in Short Interest

HCW Biologics Inc. (NASDAQ:HCWB) saw a large drop in short interest during the month of October. As of October 15th, there was short interest totaling 37,709 shares, a drop of 38.1% from the September 30th total of 60,941 shares. Approximately 1.9% of the shares of the company are short sold. Based on an average daily volume of 226,124 shares, the short-interest ratio is currently 0.2 days.

Analyst Ratings Changes

A number of research analysts have recently commented on HCWB shares. Wall Street Zen raised shares of HCW Biologics from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of HCW Biologics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, HCW Biologics currently has an average rating of “Hold” and a consensus target price of $30.00.

HCW Biologics Price Performance

Shares of HCW Biologics stock traded up $0.02 during midday trading on Monday, hitting $1.12. 51,285 shares of the company were exchanged, compared to its average volume of 1,166,428. The firm has a 50 day simple moving average of $1.92 and a 200-day simple moving average of $4.16. HCW Biologics has a 52 week low of $1.09 and a 52 week high of $23.94. The firm has a market cap of $2.51 million, a P/E ratio of -0.04 and a beta of 2.31.

HCW Biologics (NASDAQ:HCWB) last announced its earnings results on Friday, August 14th. The company reported ($11.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.98) by ($9.60). HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%. The business had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.14 million.

About HCW Biologics

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression.

HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression.